Assessment of Interleukin-10 Levels in Iraqi Diabetic Type 2 Patients Infected with Toxoplasmosis

Sarah Ali Saeed, Israa Kasim Al-Aubaidi

Abstract


Background: Toxoplasmosis is a disease caused by an obligate intracellular protozoan parasite Toxoplasma gondii that infects birds and mammals as an intermediate host while infecting cats as a definitive host. Diabetes mellitus is a global metabolic disorder that appeared due to inappropriate hyperglycemia. Interleukin-10 is an immunoregulatory cytokine that plays a main role in modulating inflammation, it’s considered  as main inhibitory cytokine against the action of inflammatory cytokines such as IL-12. The main aim of this study is to assess the levels of IL-10 in Iraqi diabetic type 2 infected with toxoplasmosis.

Methods: This study concluded 109 cases of Iraqi diabetic type 2 patients and 80 samples of healthy individuals collected from private lab in Baghdad, Iraq, during period from March to June 2022 with age mean 49.9 ± 1.29.

Results: The results showed that the group of diabetes has the highest level of glucose in diabetes diagnostic tests 7.9 ± 0.178 HbA1C, 174.55 ± 3.96 mg/dl FBS and 216.89 ± 4.96 mg/dl RBS respectively. Moreover, 51/109 samples of diabetic patients have highest level of IgG anti-Toxoplasma 34.95 ± 7.5 UI/mL in CMIA followed by 30/80 samples of healthy individuals have seropositive for the same antibody 32.7 ± 8.45 UI/mL in the same assay with significant differences While, all samples were seronegative for IgM anti-Toxoplasma. The group of healthy control has the highest levels of IL-10 in ELISA 320.43 ± 17.64 pg/ml followed by the group of diabetic patients 138.38 ± 5.69 pg/ml. Also, the concentration of this interleukin was in the group of toxoplasmosis patients which considered as a control positive 115.45 ± 4.44 pg/ml. While, the group of diabetic patients with toxoplasmosis has the lowest concentration of the interleukin 102.3 ± 7.05 pg/ml with highly significant differences.

Conclusion: The conclusion of this study is the IL-10 has been shown highest levels in healthy control in comparison with other study groups.


Full Text:

PDF

References


Dubey JP. Toxoplasmosis a waterborne zoonosis. Veterinary Parasitology, (2004); 126(1): 57–72.

AL-Mossawei MT, AL-Mossawei HM and AL-Dugaily KhY. Serological study of toxoplasmosis spread among unmarried female university using LAT, ELISA and IgG avidity. Baghdad Science Journal, (2016); 13(4): 714–720.

Montoya JG and Liesenfeld O. Toxoplasmosis. Lancet, (2004); 363(1): 1965–1976.

Al-Maamuri SD, Al-Shanawi FA and Melconian AK. Seroprevalence of Toxoplasma gondii in schizophrenic patients in Iraq using ELISA test. Iraqi Journal Science, (2014); 55(3B): 1243–1248.

Saheb EJ, Al-Issa YAH, Mussa IS and Zghair KhH. Incidence of toxoplasmosis in psoriasis patients and possible correlation with tumor necrosis factor – α. Baghdad Science Journal, (2020); 17(1): 214–219.

Hade BF, Ghareeb AM and Kawan MH. Direct amplification of B1 gene of Toxoplasma gondii DNA using nested polymerase chain reaction following microwave treatment for whole blood samples. Iraqi Journal Veterinary Medicine, (2015); 39(1): 23–27.

Chang Y, Huang Ch and Shiau M. Cytokines, metabolism and type 2 diabetes mellitus. Journal of Biomedical Laboratory Science, (2009); 21(4): 112 – 118.

Al-Tukmagi HF and Moussa MA. Quality of life of patients with type II diabetes mellitus in Al-Hilla city-Iraq. Iraqi Journal Pharmaceutical Sciences, (2014); 23(2): 99–103.

Fallowfield L. The quality of life: The missing measurement in health care, British Journal General Practice, (1990); 311 pp.

Polonsky KS. Lilly Lecture 1994. The beta cell in diabetes: from molecular genetics to clinical research. Diabetes, (1995); 44(6): 705–717.

Hanis CL, Boerwinkle E, Chakraborty R, Ellsworth DL, Concannon P, Stirling B, Morrison VA, Wapelhorst B, Spielman RS, Gogolin-Ewens KJ, Shepard JM, Williams SR, Risch N, Hinds D, Iwasaki N, Ogata M, Omori Y, Petzold C, Rietzch H, Schröder HE, Schulze J, Cox NJ, Menzel S, Boriraj VV, Chen X, Lim LR, Lindner T, Mereu LE, Wang YQ, Xiang K, Yamagata K, Yang Y and Bell GI. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nature Genetics, (1996); 13(2):161–166.

Waree P, Ferguson DJ, Pongponratn E, Chaisri U and Sukthana Y. Immunohistochemical study of acute and chronic toxoplasmosis in experimentally infected mice. Southeast Asian Journal Tropical Medicine, (2007); 38(2): 223–231.

Waree P. Toxoplasmosis: pathogenesis and immune response. Thailand. Medical Journal, (2008); 8(4): 487–496.

Petrak M and Carpenter J. Feline toxoplasmosis. Journal of the American Veterinary Medical Association, (1965); 146: 728–734.

Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care, (2004); 27(1): 813–823.

Jagannathan M, McDonnell M, Liang Y, Hasturk H, Hetzel J, Rubin D, Kantarci A, Van Dyke TE, Ganley-Leal LM and Nikolajczyk BS. Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia, (2010); 53(7):1461–1471.

Donath MY and Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, (2011); 11(2): 98–107.

Miller CM, Boulter NR, Ikin RJ and Smith NC. The Immunobiology of the innate response to Toxoplasma gondii. International Journal for Parasitology, (2009); 39(1): 23–29.

Shaw MH, Freeman GJ, Scott MF, Fox BA, Bzik DJ, Belkaid Y and Yap GS. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-c dependent IL-10 reactivation. Journal of Immunology, (2006); 176(1): 7263–7271.

Khan IA, Matsuura T and Kasper LH. IL-10 mediates immunosuppression following primary infection with Toxoplasma gondii in mice. Parasite Immunology, (1995); 17(4): 185–195.

Neyer LE, Grunig G, Remington JS, Rennick D and Hunter CA. Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infection and Immunity (1997); 65(5): 1675–1682.

SAS. Statistical Analysis System, User's Guide. Statistical. Version 9.6th ed. SAS. (2018).

Akinbo FO, Omoregie R, Egbe E. Intestinal parasitic infections among diabetes mellitus patients. Biomarkers and Genomic Medicine, (2013); 5(1–2):44–7.

Saki J, Shafieenia S, Foroutan-Rad M. Seroprevalence of toxoplasmosis in diabetic pregnant women in southwestern of Iran. Journal of Parasitic Diseases, (2016); 40(4): 1586–1589.

Saki J, Khodkar I, Shadnoosh F, Safi M, Ghadiri A and Shafieenia Sh. Study of toxoplasmosis in type 2 diabetic patients using ELISA and B1 nested-PCR methods. Annals of parasitology, (2022); 68(2): 367–373.

Elkholy AA, Omar RE, Elbadayw AM, Elawady MA and Abou-Ouf E. Investigating the potential link between seroprevalence of Toxoplasma IgG and both types of diabetes mellitus in Benha city, Egypt. Parasitology University Journal, (2022); 15(2): 195–201.

Hammed IK, Abed BA and Rashid NF. Glycated hemoglobin as a dual biomarker association between HbA1C and dyslipidemia in type 2 diabetic patients. Journal of Faculty Medicine Baghdad, (2012); 54(1): 88–92.

Taher MA, Mosutafa MM and Mahmood AS. Measurements of HbA1c for patients with diabetes mellitus and foot ulceration. Iraqi Journal Pharmaceutical Sciences, (2011); 20(1): 19–24.

Alnidawi Bf. Association between glycemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. AL-Kindy College Medicine Journal, (2015); 11(2): 10-14.

Cavallazzi LO. Toxoplasmosis of the central nervous system in a diabetic patient. Arq Neuropsiquiatr, (1985); 43(3): 319–321.

Mousawy KhM. Possible role of interleukins 6 and 10 in colorectal carcinoma in Iraqi patients. Journal of Faculty Medicine Baghdad, (2004); 47(1): 86–88.

Minshawi F, Lanvermann S, MecKenzi E, Jeffery R, Couper K, Papoutsopoulou S, Roers A and Muller W. The generation of an engineered interleukin-10 protein with improved stability and biological function. Frontiers Immunology, (2020); 11(1794): 1–18.

Mohamed KI, khadhum MS, Abu-Al-Ess HQ, Mohammed Ali, SH, Al-Fukhar SA, Al-Wattar, W.M.; Hamoudi, S.R. and Mousa, J.M. The effect of Toxoplasma gondii on interleukin-8, interleukin-10, leukotriene B4 and calcium levels in aborted women. International Journal of medical Research and Health Sciences, (2017); 6(11): 76–82.

Marietta EV, Chen Y and Weis JH. Modulation of expression of the anti‐inflammatory cytokines interleukin‐13 and interleukin‐10 by interleukin‐3. European Journal Immunology, (1996); 26(1): 49–56.

Grossmann V, Schmitt VH, Zeller T, Panova-Noeva M, Schulz A, Laubert-Reh D, Juenger C, Schnabel RB, Abt TG, Laskowski R, Wiltink J, Schulz E, Blankenberg S, Lackner KJ, Münzel T and Wild PS. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care, (2015); 38(7): 1356–1364.

Naz S, Shafique N, Sharif S, Manzoor F, Saifi S, Firasat S and Kaul H. Association of interleukin 10 (IL-10) gene with type 2 diabetes mellitus by single nucleotide polymorphism of its promotor region

G/A 1082. Critical ReviewsTM Eukaryotic Gene Expression, (2020); 30(4): 285–289.

Khan IA, Tadashi M and Lioyd HK. IL-10 mediates immunosuppression following primary infection with Toxoplasma gondii in mice. Parasite Immunology, (1995); 7(4): 185–195.

Lang C, Gross U and Lüder CG. Subversion of innate and adaptive immune responses by Toxoplasma gondii. Parasitology Research, (2007); 100(2):191–203.

Alani MM. Serum interleukin 1 and interleukin 10 levels I Iraqi leukemic patients with hepatitis G virus infection. Journal of Faculty Medicine Baghdad, (2012); 54(4). 340–343.

Kanash AK and Yousif JJ. The association of toxoplasmosis and the levels of IL-10 and IL-12 in women with breast cancer. International Journal of Drug Delivery Technology, (2021); 11(2): 265-268.


Refbacks

  • There are currently no refbacks.